<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Antimetabolites; Methotrexate: malignant disease; Methotrexate: malignant disease; Leukaemia: acute: lymphoblastic; Choriocarcinoma; Leukaemia: CNS, prophylaxis; Meningeal carcinoma; Methotrexate: malignant disease; Capecitabine; Cytarabine; Fludarabine; Leukaemia: chronic lymphocytic; CLL see Leukaemia, chronic lymphocytic; Cladribine; Clofarabine; Leukaemia: acute; Nelarabine; Gemcitabine; Fluorouracil: malignant disease; Pemetrexed; Raltitrexed; Mercaptopurine: malignant disease; Tegafur; Tioguanine; Thioguanine see Tioguanine; Azacitidine" /><meta name="IX" content="Antimetabolites; Methotrexate: malignant disease; Methotrexate: malignant disease; Leukaemia: acute: lymphoblastic; Choriocarcinoma; Leukaemia: CNS, prophylaxis; Meningeal carcinoma; Methotrexate: malignant disease; Capecitabine; Cytarabine; Fludarabine; Leukaemia: chronic lymphocytic; Cladribine; Clofarabine; Leukaemia: acute; Nelarabine; Gemcitabine; Fluorouracil: malignant disease; Pemetrexed; Raltitrexed; Mercaptopurine: malignant disease; Tegafur; Tioguanine; Azacitidine" /><meta name="IXN" content="CLL see Leukaemia, chronic lymphocytic; Thioguanine see Tioguanine" /><title>8.1.3 Antimetabolites: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4725.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4725.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4725.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4676.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4721.htm" title="Previous: MITOXANTRONE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="202601.htm" title="Next: AZACITIDINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4725">8.1.3 Antimetabolites</h1><?highlighter on?><div id="pC" class="jN"><div><p>Antimetabolites are incorporated into new nuclear material or combine
irreversibly with cellular enzymes, preventing normal cellular division.</p><div id="_1199884354297"><p><b><span>Methotrexate</span> </b>inhibits the enzyme dihydrofolate
reductase, essential for the synthesis of purines and pyrimidines.
It is given by mouth, intravenously, intramuscularly, or intrathecally.</p><p><span>Methotrexate</span> is used as maintenance therapy for
childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, non-Hodgkin’s lymphoma,
and a number of solid tumours. Intrathecal <span>methotrexate</span> is used in the CNS prophylaxis of childhood acute lymphoblastic leukaemia, and as
a therapy for established meningeal cancer or lymphoma.</p><p><span>Methotrexate</span> causes myelosuppression, mucositis,
and rarely pneumonitis. <span id="_4725.3">It is <b>contra-indicated </b>in significant renal impairment because it is excreted primarily
by the kidney. It is also contra-indicated in patients with severe
hepatic impairment. It should also be <b>avoided</b> in
the presence of significant pleural effusion or ascites because it
can accumulate in these fluids, and its subsequent return to the circulation
may cause myelosuppression.</span> <span id="_4725.4">Systemic toxicity may
follow intrathecal administration and blood counts should be carefully
monitored</span>.</p><p>Folinic acid (<a title=" Cytotoxic drugs" href="4676.htm#_4676">section 8.1</a>) following <span>methotrexate</span> administration
helps to prevent <span>methotrexate</span>-induced mucositis
or myelosuppression.<span id="_4725.26"></span></p></div><div id="_1199884423128"><p><b>Capecitabine</b>, which is metabolised to fluorouracil, is given by mouth. It is
licensed as monotherapy or combination therapy for adjuvant treatment
of advanced colon cancer following surgery, for monotherapy or combination
therapy of metastatic colorectal cancer, and for first-line treatment
of advanced gastric cancer in combination with a platinum-based regimen.
Capecitabine is also licensed for second-line treatment of locally
advanced or metastatic breast cancer either in combination with docetaxel
(where previous therapy included an anthracycline) or alone (after
failure of a taxane and anthracycline regimen or where further anthracycline
treatment is not indicated). For the role of capecitabine in the treatment
of breast cancer, see <a title="BNF:sub-sub-section: Breast cancer" href="4821.htm#_4821">section 8.3.4.1</a>.</p></div><div id="_4725.10"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Capecitabine and oxaliplatin in the adjuvant treatment
of stage III (Dukes’ C) colon cancer (April 2006)</h3><p>Capecitabine alone <i>or</i> oxaliplatin combined
with fluorouracil and folinic acid are options for adjuvant treatment
following surgery for stage III (Dukes’ C) colon cancer.</p></div></div><div id="_4725.2"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Capecitabine and tegafur with uracil for metastatic
colorectal cancer (May 2003)</h3><p>Capecitabine or tegafur with uracil (in combination with folinic
acid) is an option for the first-line treatment of metastatic colorectal
cancer.</p></div></div><div id="_1199884496724"><p><span><b>Cytarabine</b></span> acts by interfering with pyrimidine
synthesis. It is given subcutaneously, intravenously, or intrathecally.
Its predominant use is in the induction of remission of acute myeloblastic
leukaemia. <span id="_4725.5">It is
a potent myelosuppressant and requires careful haematological
monitoring</span>. A liposomal formulation of
cytarabine for intrathecal use is licensed for lymphomatous meningitis.</p></div><div id="_1199884537100"><p><b>Fludarabine</b> is licensed for the initial treatment of advanced B-cell chronic lymphocytic
leukaemia (CLL) or after first-line treatment in
patients with sufficient bone-marrow reserves; it is usually given
by mouth, but can be given by intravenous injection or infusion. <span id="_4725.6">Fludarabine is well tolerated
but it does cause myelosuppression, which may be cumulative. Immunosuppression
is also common (see panel on cladribine and fludarabine below), and
co-trimoxazole is used to prevent pneumocystis infection.</span> Immune-mediated haemolytic anaemia, thrombocytopenia, and neutropenia
are less common side-effects.</p></div><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (October 2006) that fludarabine is accepted for restricted
use for the treatment of B-cell chronic lymphocytic leukaemia (CLL)
in patients with sufficient bone marrow reserves. First-line treatment
should only be initiated in patients with advanced disease, Rai stages
III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where
the patient has disease-related symptoms or evidence of progressive
disease.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Fludarabine monotherapy for the first-line treatment
of chronic lymphocytic leukaemia (February 2007)</h3><p>Fludarabine monotherapy, is <b>not</b> recommended
for the first-line treatment of chronic lymphocytic leukaemia.</p></div><div id="_1199884572836"><p><span><b>Cladribine</b></span> is given by intravenous infusion for the treatment of
hairy cell leukaemia. It is also given for chronic lymphocytic leukaemia
in patients who have failed to respond to standard regimens containing
an alkylating agent. Cladribine produces severe myelosuppression,
with neutropenia, anaemia, and thrombocytopenia; haemolytic anaemia
has also been reported. High doses of cladribine have been associated
with acute renal failure and severe neurotoxicity.</p></div><div id="_4725.7"><div class="cN"><p><b>Cladribine</b> and <b>fludarabine</b> have a potent and prolonged immunosuppresive effect. <span id="_201078">Patients treated with cladribine or fludarabine are
more prone to serious bacterial, opportunistic fungal, and viral infections,
and prophylactic therapy is recommended in those at risk. To prevent potentially fatal transfusion-related graft-versus-host
reaction, only irradiated blood products should be administered.</span> Prescribers should <span id="_4725.24">consult
specialist literature</span> when using highly
immunosuppressive drugs.</p></div></div><div id="_1199884630197"><p><b>Clofarabine</b> is licensed for the treatment of acute lymphoblastic leukaemia in
patients aged 1 to 21 years who have relapsed or are refractory after
receiving at least two previous regimens. It is given by intravenous
infusion.</p></div><div id="_200232"><p><b>Nelarabine</b> is
licensed for the treatment of T-cell acute lymphoblastic leukaemia
and T-cell lymphoblastic lymphoma in patients who have relapsed or
who are refractory after receiving at least two previous regimens.
It is given by intravenous infusion. Neurotoxicity is common with
nelarabine and close monitoring for neurological adverse
events is strongly recommended—discontinue
if neurotoxicity occurs.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (March 2008) that the use of nelarabine (<span class="cZ">Atriance</span>®) within NHS Scotland is restricted to bridging treatment before
stem cell transplantation.</p></div><div id="_1199884660682"><p><span><b>Gemcitabine</b></span> is used intravenously; it is given
alone for elderly patients or for palliative treatment, or with <span>cisplatin</span> as first-line treatment for locally advanced
or metastatic non-small cell lung cancer. It is also used in the treatment
of locally advanced or metastatic pancreatic cancer (see <a title="target-block: Gemcitabine (NICE guidance Pancreatic cancer)" href="4725.htm#_4725.27">NICE guidance</a> below). Combined
with cisplatin, <span>gemcitabine</span> is also licensed for
the treatment of advanced bladder cancer. Combined with carboplatin,
gemcitabine is licensed for the treatment of locally advanced or metastatic
epithelial ovarian cancer which has relapsed after a recurrence-free
interval of at least 6 months following previous platinum-based therapy.
Combined with paclitaxel, gemcitabine is also licensed for the treatment
of metastatic breast cancer which has relapsed after previous chemotherapy
including an anthracycline (see <a title="target-block: Gemcitabine (NICE guidance breast cancer)" href="4725.htm#_4725.28">NICE guidance</a> below). Gemcitabine
is generally well tolerated but it can cause mild gastro-intestinal
side-effects, musculoskeletal pain, influenza-like symptoms and rashes;
renal impairment and pulmonary toxicity have also been reported. <span id="_4725.8">Haemolytic uraemic syndrome has
been reported rarely and <span>gemcitabine</span> should be discontinued if signs of microangiopathic haemolytic anaemia
occur.</span></p></div><p>The <i>Scottish Medicines Consortium</i> has advised (November 2006) that gemcitabine is accepted for restricted
use for the treatment of metastatic breast cancer, which has relapsed
following previous chemotherapy including an anthracycline (unless
contra-indicated).</p><div id="_4725.28"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Gemcitabine for the treatment of metastatic breast
cancer (January 2007)</h3><p>Gemcitabine, in combination with paclitaxel, is an option for
the treatment of metastatic breast cancer <b>only</b> when
docetaxel monotherapy or docetaxel plus capecitabine are also considered
appropriate.</p></div></div><div id="_4725.27"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Gemcitabine for the treatment of pancreatic cancer
(May 2001)</h3><p>Gemcitabine is an option for first-line chemotherapy for patients
with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky
score of at least 50 [Karnofsky score is a measure of the ability
to perform ordinary tasks].</p><p>Gemcitabine is not recommended for patients who can have potentially
curative surgery. There is insufficient evidence about its use for
second-line treatment of pancreatic adenocarcinoma.</p></div></div><div id="_1199884976708"><p><span><b>Fluorouracil</b></span> is used to treat a number of solid tumours, including
gastro-intestinal tract cancers and breast cancer. It is commonly
used with folinic acid in advanced colorectal cancer. It may also
be used topically for certain malignant and pre-malignant skin lesions.
Toxicity is unusual, but may include myelosuppression, mucositis,
and rarely a cerebellar syndrome. <span id="_4725.25">On prolonged infusion, a
desquamative hand–foot syndrome may occur.</span></p></div><div id="_1199885035350"><p><b>Pemetrexed</b> inhibits thymidylate transferase and other folate-dependent enzymes.
It is licensed for use with cisplatin for the treatment of unresectable
malignant pleural mesothelioma which has not previously been treated
with chemotherapy (see <a title="target-block: Pemetrexed NICE Guidance pleural mesothelioma" href="4725.htm#_200862">NICE guidance</a>, below).
Pemetrexed is also licensed for use with cisplatin for the first-line
treatment of locally advanced or metastatic non-small cell lung cancer
other than predominantly squamous cell histology (see <a title="BNF:target-block: pemetrexed nice 2009" href="4725.htm#_204217">NICE guidance</a>, below), and as monotherapy for
its second-line treatment (but see <a title="target-block: Pemtrexed NICE guidance non-small-cell lung cancer" href="4725.htm#_200322">NICE guidance</a>, below).
It is also licensed as monotherapy for maintenance treatment in locally
advanced or metastatic non-small cell lung cancer other than predominantly
squamous cell histology that has not progressed immediately following
combination therapy of a platinum compound with either gemcitabine,
paclitaxel, or docetaxel. Pemetrexed is given by intravenous infusion.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (July 2005) that pemetrexed (<span class="cZ">Alimta®</span>) in combination with cisplatin is accepted for restricted use within
NHS Scotland for previously untreated patients with stage III/IV unresectable
malignant pleural mesothelioma.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (January 2010) that pemetrexed (<span class="cZ">Alimta</span>®) is accepted for restricted use within NHS Scotland in combination
with cisplatin for the first-line treatment of locally advanced or
metastatic non-small cell lung cancer other than predominantly squamous
cell histology; it is restricted to patients in whom the histology
of the tumour has been confirmed as adenocarcinoma or large cell carcinoma.</p></div><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (August 2008) that pemetrexed (<span class="cZ">Alimta</span>®) is accepted for restricted use within NHS Scotland as monotherapy
for the second-line treatment of locally advanced or metastatic non-small
cell lung cancer without predominantly squamous cell histology; it
is restricted for use in patients with good performance status who
would otherwise be eligible for docetaxel treatment.</p><div id="_200862"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Pemetrexed for the treatment of malignant pleural
mesothelioma (January 2008)</h3><p>Pemetrexed is an option for the treatment of malignant pleural
mesothelioma only in patients who have a WHO performance status of
0 or 1 [WHO performance status is a measure of the ability to perform
ordinary tasks], who are considered to have advanced disease and for
whom surgical resection is considered inappropriate.</p></div></div><div id="_204217"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Pemetrexed for the first-line treatment of non-small
cell lung cancer (September 2009)</h3><p>Pemetrexed, in combination with cisplatin, is an option for
the first-line treatment of locally advanced or metastatic non-small
cell lung cancer only if the histology of the tumour has been confirmed
as adenocarcinoma or large-cell carcinoma.</p></div></div><div id="_200322"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Pemetrexed for the treatment of non-small cell lung
cancer (August 2007)</h3><p>Pemetrexed is <b>not</b> recommended for the treatment
of locally advanced or metastatic non-small cell lung cancer which
has previously been treated with chemotherapy.</p></div></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Pemetrexed for the treatment of non-small cell lung
cancer (June 2010)</h3><p>Pemetrexed is an option for the maintenance treatment of locally
advanced or metastatic non-small cell lung cancer other than predominantly
squamous cell histology that has not progressed immediately following
combination therapy of a platinum compound with either gemcitabine,
paclitaxel, or docetaxel.</p></div><div id="_1199885094087"><p><span><b>Raltitrexed</b></span>, a thymidylate synthase inhibitor, is given intravenously
for palliation of advanced colorectal cancer when <span>fluorouracil</span> and folinic acid cannot be used. It is probably of similar efficacy
to <span>fluorouracil</span>. <span>Raltitrexed</span> is generally well tolerated, but can cause marked myelosuppression
and gastro-intestinal side-effects.</p></div><div class="cN"><h3 class="cBP">NICE guidance (irinotecan, oxaliplatin and raltitrexed
for advanced colorectal cancer)</h3><p> See <a title="target-block: NICE: irinotecan" href="67743.htm#_67743.2">Platinum Compounds</a></p></div><div id="_1199885133182"><p><span><b>Mercaptopurine</b></span> is used as maintenance
therapy for the acute leukaemias and in the management of ulcerative
colitis and Crohn’s disease (<a title="BNF:monograph: MERCAPTOPURINE" href="201298.htm#_201298">section 1.5.3</a>). <span id="_4725.9"><span>Azathioprine</span>, which
is metabolised to <span>mercaptopurine</span>, is generally
used as an immunosuppressant (<a title=" Antiproliferative immunosuppressants" href="4778.htm#_4778">section 8.2.1</a> and <a title="sub-section: Drugs which suppress the rheumatic disease process" href="5288.htm#_5288">section 10.1.3</a>). The
dose of both drugs should be reduced if the patient is receiving <span>allopurinol</span> since it interferes with their metabolism.</span></p></div><div id="_1199885164011"><p><b>Tegafur</b> (in combination with uracil) is given by mouth, together with calcium
folinate, in the management of metastatic colorectal cancer. Tegafur
is a prodrug of fluorouracil; uracil inhibits the degradation of fluorouracil.
Tegafur (with uracil) has been shown to be of similar efficacy as
a combination of fluorouracil and folinic acid for metastatic colorectal
cancer. For NICE guidance on capecitabine and tegafur with uracil
for metastatic colorectal cancer, see <a title="target-block: NICE guidance, capecitabine and tegafur with uracil" href="4725.htm#_4725.2">above</a>.</p></div><div id="_4725.29"><p><span><b>Tioguanine</b></span> is given by mouth
for the treatment of acute leukaemias and chronic myeloid leukaemia.
It can be given at various stages of treatment in short-term cycles.
Tioguanine has a lower incidence of gastro-intestinal side-effects
than mercaptopurine. Long-term therapy is no longer recommended because
of the high risk of liver toxicity; treatment with tioguanine should
be discontinued if liver toxicity develops.</p></div><div id="_204021"><p><b>Azacitidine</b> is
a pyrimidine analogue that is given by subcutaneous injection. It
is used in the treatment of intermediate-2 and high-risk myelodysplastic
syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia,
in adults who are not eligible for haemotopoietic stem cell transplantation.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Azacitidine for the treatment of myelodysplastic
syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
(March 2011)</h3><p>Azacitidine is recommended in adults who are not eligible for
haemotopoietic stem cell transplantation as an option for the treatment
of intermediate-2 and high-risk myelodysplastic syndromes, chronic
myelomonocytic leukaemia, or acute myeloid leukaemia.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_202601"><a href="202601.htm" title="AZACITIDINE">AZACITIDINE</a></li><li id="_106025"><a href="106025.htm" title="CAPECITABINE">CAPECITABINE</a></li><li id="_36783"><a href="36783.htm" title="CLADRIBINE">CLADRIBINE</a></li><li id="_129822"><a href="129822.htm" title="CLOFARABINE">CLOFARABINE</a></li><li id="_4726"><a href="4726.htm" title="CYTARABINE">CYTARABINE</a></li><li id="_27475"><a href="27475.htm" title="FLUDARABINE PHOSPHATE">FLUDARABINE PHOSPHATE</a></li><li id="_4731"><a href="4731.htm" title="FLUOROURACIL">FLUOROURACIL</a></li><li id="_37649"><a href="37649.htm" title="GEMCITABINE">GEMCITABINE</a></li><li id="_4735"><a href="4735.htm" title="MERCAPTOPURINE">MERCAPTOPURINE</a></li><li id="_4737"><a href="4737.htm" title="METHOTREXATE">METHOTREXATE</a></li><li id="_200049"><a href="200049.htm" title="NELARABINE">NELARABINE</a></li><li id="_129178"><a href="129178.htm" title="PEMETREXED">PEMETREXED</a></li><li id="_39236"><a href="39236.htm" title="RALTITREXED">RALTITREXED</a></li><li id="_106026"><a href="106026.htm" title="TEGAFUR WITH URACIL">TEGAFUR WITH URACIL</a></li><li id="_4740"><a href="4740.htm" title="TIOGUANINE">TIOGUANINE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4721.htm">Previous: MITOXANTRONE</a> | <a class="top" href="4725.htm#">Top</a> | <a accesskey="]" href="202601.htm">Next: AZACITIDINE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>